Also trades as: ENLV.TA (TLV) · $vol 0M
ENLV NASDAQ
Enlivex Therapeutics Ltd.
1W: -24.6%
1M: -67.2%
3M: -92.5%
YTD: -98.5%
1Y: -99.0%
3Y: -99.2%
5Y: -99.9%
$2.70
+0.10 (+3.72%)
Weekly Expected Move ±14.7%
$0
$0
$0
$0
$0
Credit Risk of going bust: higher than 96% of companies Debt: 85.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.77 (down 34%), Enlivex Therapeutics Ltd. would be worth roughly what it owes.
Total debt $17.2M against a stock market value of $2.8M.
Distance to default 0.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $16.9M (short-term plus half of long-term), stock volatility 108.6%; Altman Z'' 11.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $17.2M against a stock market value of $2.8M.
Distance to default 0.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $16.9M (short-term plus half of long-term), stock volatility 108.6%; Altman Z'' 11.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
📊 Key Metrics
TTM$0M
Revenue
+0.0% YoY
$4B
Net Income
+31455.8% YoY
$-16M
Free Cash Flow
-28.0% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE209.7%
ROA166.9%
ROIC-0.4%
Valuation
P/E0.0
P/B0.0
EV/EBITDA-8.6
Leverage
Debt/Equity0.00
Current Ratio119.39
Interest Cov.-15.2x
Quality Scores
Piotroski F5/9
Altman Z1.87
Beneish M0.00